--- title: "242,229 Shares in Ventyx Biosciences, Inc. $VTYX Acquired by GSA Capital Partners LLP" type: "News" locale: "en" url: "https://longbridge.com/en/news/276532691.md" description: "GSA Capital Partners LLP acquired 242,229 shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) valued at approximately $753,000, representing about 0.34% ownership. This acquisition occurred in the third quarter, as per the latest SEC filing. Other institutional investors have also recently adjusted their stakes in Ventyx. Analysts have downgraded the stock's ratings, with a consensus price target of $14.00. Ventyx's stock opened at $13.97, with a market cap of $1 billion and a 12-month price range of $0.78 to $25.00." datetime: "2026-02-22T10:21:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276532691.md) - [en](https://longbridge.com/en/news/276532691.md) - [zh-HK](https://longbridge.com/zh-HK/news/276532691.md) generator: "portal-rs" --- # 242,229 Shares in Ventyx Biosciences, Inc. $VTYX Acquired by GSA Capital Partners LLP GSA Capital Partners LLP acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 242,229 shares of the company's stock, valued at approximately $753,000. GSA Capital Partners LLP owned about 0.34% of Ventyx Biosciences at the end of the most recent reporting period. Get **Ventyx Biosciences** alerts: - Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns Several other large investors have also recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP acquired a new position in shares of Ventyx Biosciences during the second quarter valued at $34,000. Engineers Gate Manager LP bought a new stake in Ventyx Biosciences in the 2nd quarter valued at about $42,000. Jump Financial LLC acquired a new position in Ventyx Biosciences during the 2nd quarter valued at about $53,000. Jane Street Group LLC acquired a new position in Ventyx Biosciences during the 1st quarter valued at about $56,000. Finally, Ameriprise Financial Inc. bought a new position in Ventyx Biosciences in the 2nd quarter worth about $60,000. 97.88% of the stock is owned by institutional investors and hedge funds. ## Analyst Ratings Changes Several equities research analysts have commented on VTYX shares. Oppenheimer lowered shares of Ventyx Biosciences from an "outperform" rating to a "market perform" rating in a research note on Thursday, January 8th. Clear Str lowered Ventyx Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, January 7th. Lifesci Capital reaffirmed a "market perform" rating and set a $14.00 target price on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Piper Sandler lowered Ventyx Biosciences from an "overweight" rating to a "hold" rating and set a $14.00 price target for the company. in a research report on Thursday, January 8th. Finally, HC Wainwright lowered Ventyx Biosciences from a "buy" rating to a "neutral" rating and set a $14.00 price target on the stock. in a report on Thursday, January 8th. Eight analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Reduce" and a consensus price target of $14.00. **View Our Latest Research Report on Ventyx Biosciences** ## Ventyx Biosciences Price Performance Shares of NASDAQ:VTYX opened at $13.97 on Friday. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -9.31 and a beta of 1.25. Ventyx Biosciences, Inc. has a 12 month low of $0.78 and a 12 month high of $25.00. The stock's 50 day moving average price is $12.17 and its 200 day moving average price is $7.66. ## Insider Transactions at Ventyx Biosciences In related news, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the transaction, the chief executive officer directly owned 2,372,863 shares of the company's stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John Nuss sold 12,675 shares of the company's stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares of the company's stock, valued at $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.49% of the stock is owned by insiders. ## Ventyx Biosciences Company Profile (Free Report) Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. ## See Also - Five stocks we like better than Ventyx Biosciences - \~$1.5T SpaceX IPO: Pre-IPO Opportunity - Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4 - How a Family Trust May Be Able To Help Preserve Your Wealth - This makes me furious - Elon Musk: This Could Turn $100 into $100,000 **Want to see what other hedge funds are holding VTYX?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Ventyx Biosciences Right Now? Before you consider Ventyx Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list. While Ventyx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [VTYX.US](https://longbridge.com/en/quote/VTYX.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**